针对9p21-缺陷质母细胞瘤中合成致命弱点的网络向组合疗法:一个案例报告

Michael P Castro1,2,3, Kristin Dittmar4

  • 1Department of Oncology, Personalized Cancer Medicine, PLLC, Los Angeles, California, USA.

Neuro-oncology advances
|January 8, 2024
PubMed
概括

这项研究强调了如何针对合成致命漏洞,如CDKN2A和MTAP在质母细胞瘤中的损失,可以导致患者显著的缓解. 这种方法为精准医学在治疗侵略性脑瘤方面提供了一个有希望的途径.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K